期刊文献+

磷酰肌醇-3激酶途径与bcr/abl基因介导的白血病细胞增殖和抗凋亡信号传导

The effects of the phosphatidylinositol 3-kinase pathway on the leukemia cell's proliferation and anti-apoptosis induced by bcr/abl oncogene.
下载PDF
导出
摘要 目的探讨磷酰肌醇-3激酶途径在K562、NB4和HL60细胞增殖和凋亡抗性中的不同作用。方法短期培养法直接法G显带检测K562细胞和CML患者骨髓原代细胞的染色体核型,RQ-PCR检测K562细胞和CML患者骨髓原代细胞的bcr/abl基因;用磷酰肌醇-3激酶特异抑制剂渥曼青霉素(WT)抑制磷酰肌醇-3激酶活性,经细胞生长曲线测定、半固体集落形成实验、流式细胞膜联蛋白V标记技术检测细胞凋亡百分比和凋亡指数。观察K562、NB4和HL60细胞增殖能力及凋亡抗性的变化。统计学采用t检验。结果K562细胞G显带检出Ph染色体,RQ-PCR检测K562细胞存在bcr/abl基因;与标准Ph染色体表达的CML患者骨髓原代细胞的bcr/abl基因完全吻合;K562、NB4和HL60细胞在24h、48h、72h的增殖抑制率分别为41.33%、57.46%、65.85%和26.29%、5.51%、2.10%及32.14%、17.14%、13.14%。生长曲线显示WT抑制磷酰肌醇-3激酶途径可显著抑制K562细胞的增殖(P<0.05),而对NB4和HL60细胞增殖无明显影响(P>0.05)。K562、NB4和HL60细胞加和不加WT,培养14d后的集落形成率分别为:16.15%和7.60%,5.90%和6.10%,6.60%和6.40%。集落形成抑制率为52.94%、3.39%和3.03%。WT抑制磷酰肌醇-3激酶途径可显著抑制K562细胞的集落形成(P<0.05),而对NB4和HL60细胞集落形成无明显影响(P>0.05)。K562、NB4和HL60细胞加WT,AraC,WT+AraC作用24h后的凋亡细胞百分比分别为(17.27±1.94)%、(17.00±3.36)%、(27.60±4.36)%;(13.25±4.12)%、(20.55±8.57)%、(17.56±7.97)%;(11.60±1.27)%、(22.07±5.62)%、(20.50±7.97)%。凋亡指数分别为8.91±3.86、6.88±2.66、13.39±4.49;7.79±2.75、9.35±4.19、7.61±6.35;3.03±0.56、3.79±0.93、5.27±2.69。提示渥曼青霉素抑制磷酰肌醇-3激酶途径可促进由AraC诱导下的K562细胞的凋亡(P<0.05),而对NB4和HL60细胞凋亡无明显影响(P均>0.05),NB4和HL60细胞凋亡主要受药物的细胞毒作用。结论渥曼青霉素可以通过抑制磷酰肌醇-3激酶通路抑制K562细胞的增殖,促进K562细胞的凋亡。磷酰肌醇-3激酶途径通路是bcr/abl基因介导的白血病细胞增殖和抗凋亡信号传导的重要信号传导途径。 Objective To investigate the effects of the phosphatidylinositol 3-kinase(PI3K) pathway on the leukemia cell's proliferation and anti-apoptosis induced by bcr/abl oncogene.Methods We determined the chromosome types of the primary cells of K562 cells and the cells in CML patients bone marrow by direct investigating of the G-banding after a short time culture, and detected the level of bcr/abl gene by RQ-PCR. We inhibited the activity of the PI3K by using Wortmannin(WT).We counted the cell's clones on semisolid medium and detected the cells growth curves. We obtained the percentage of the apoptosis cells and the apoptosis index(AI), and analysed the different potentials of proliferation and anti-apoptosis among K562 cells,NB4 cells and HL60 cells. Differences between the values were determined using Student's t-test. Significance was determined as P 〈 0.05.Results The K562 cells expressed bcr/abl gene.The inhibition rates of proliferation in K562 cells at 24h,48h and 72h were 41.33%,57.3% and 65.85%,while in NB4 cells were 26.29%,5.51% and 2.10%,and in HL60 cells were 32.14%,17.14%and 13.14%.We found that the proliferation of K562 cells was suppressed significantly by inhibition of the PI3K pathway(P 〈 0.05),but there was no marked difference in NB4 cells and HL60 cells(P 〉 0.05).The rates of clonal formation in K562 cells,NB4 cells and HL60 cells separately were 16.15%,5.90%and 6.10% after cultured for 14d,while in the control groups were 7.60%, 6.10% and 6.40% .The results suggested that the clonal formation were suppressed markedly because the PI3k was inhibited by WT(P 〈 0.05),and there had no difference in NB4 cells and HL60cells(P 〉 0.05). The percentages of apoptosis cells in K562 cells which cultured with WT,AraC and WT+AraC were 17.27±1.94%,17.00±3.36% and 27.60±4.36%;13.25±4.12%,20.55±8.57% and 17.56±7.97%; and 11.60±1.27%, 22.07±5.62%, and 20.50±7.97%. The apoptotic index(AI) of these cells were 8.91±3.86,6.88±2.66 and 13.39±4.49; 7.79±2.75,9.35±4.19 and 7.61±6.35; 3.03±0.56,3.79±0.93 and 5.27±2.69. The results suggested that it promoted the apoptosis of the K562 cells induced by AraC,the PI3K pathway was inhibited by WT,at the same time there had no notable effects on the apoptosis of NB4 and HL60 cells,which were controlled by drugs cytotoxic effects.Conelusion WT can promote the apoptosis and suppress the proliferation of K562 cells throuth inhibiting the PI3k pathway.The PI3k pathway is an important transmission path in the leukemia cells' proliferation and anti-apoptosis induced by bcr/abl oncogene.
出处 《云南医药》 CAS 2008年第2期114-118,共5页 Medicine and Pharmacy of Yunnan
基金 云南省自然科学基金(2000C0030Q)资助项目。
关键词 磷酰肌醇-3激酶 bcr/abl融合癌基因 渥曼青霉素 Phosphatidylinositol 3-kinase pathway bcr/abl oncogene Wortmannin
  • 相关文献

参考文献11

  • 1SATTLER M,SALGIA R.Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL [J].Cytokine Growth Factor Rev, 1997,8 (1): 63 -79.
  • 2HU Q, KLIPPEL A,MUSLIN AJ,et al. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase [J].Science,1995,286: 100-102.
  • 3KLIPPEL A, REINHARD C, KAVANAUGH WM, et al. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal transducing kinase pathways [J].Mol Cell Biol, 1996,16( 11):4117-4127.
  • 4CARPENTER CL, CANTLEY LC.Phosphoinositide kinases [J]. Biochemistry, 1990,29(3) 1147-1156.
  • 5OTSU M,HILES I,GOUT I,et al.Charcterization of two 85kD proteins that associate with receptor tyrosine kinases, middle-T/pp 60 c-src complexes,and PI3-kinase [J]. Cell, 1991,65(1):91-104.
  • 6SKORSKI T, KANAKARAI P, NIEBOROWSKA-SKORSKA M,et al. Phosphatidylinositol-3 kinase activity is regulated by bcr/abl and is required for the growth of Philadelphia chromosome-positive cells [J].Blood,1995,86 (1):726-730.
  • 7POWIS G, BONJOUKLIAN R, BERGGREN MM, et al. Wortmannin,a potent and selective inhibitor of phosphatidylinositol-3 kinase [J].Cancer Res,1994,54 (6): 2419-2423.
  • 8MCGAHONA, BISSONNETTE R, SCHMITT M, et al. BCR/ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death[J]. Blood, 1994,83 (3): 1179 -1183.
  • 9KABAROWSKI JH, ALLEN PB, WIEDEMANN LM. A temperature sensitive p210 bcr/abl mulant defines the primary consequences of bcr/abl tyrosine expression in growth factor dependent cells [J].EMBO J, 1994,13( 12):5887-5891
  • 10JAIN SK, LANGDON WY, VARTICOVSKI L. Tyrosine phosphorylation of p120 cbl in bcr/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase [J].Oneogene,1997,14 (5): 2217-2223.

二级参考文献10

  • 1Gu BW, Hu J, Xu L, et al. Feasibility and clinical significance of real-time quantitative RT-PCR assay of PML-RARα fusion transcript in patients with acute promyelocytic leukemia. Hemato J, 2001,2: 330-340.
  • 2Lin F, van Rhee F, Goldman JM, et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood,1996, 87:4473-4478.
  • 3Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia, 2002,16:1579-1583.
  • 4Cross NC. Minimal residual disease in chronic myeloid leukaemia. Hematol Cell Ther, 1998,40:224-228.
  • 5Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant, 1994, 14:505-509.
  • 6Elmaagacli AH, Beelen DW, Opalka B, et al. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol, 2000,79:424-431.
  • 7Neumann F, Herold C, Hildebrandt B, et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol, 2003,70:1-10.
  • 8Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol, 1999,107:587-599.
  • 9Muller MC, Gattermann N, Lahaye T, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia, 2003,17:2392-2400.
  • 10Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alpha plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia, 2003,17:2401-2409.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部